Non-dilutive capital strategy
SBIR/STTR strategy and proposal development for biomedical, digital-health, medical-device, and healthcare-AI companies.
Company information
Funding Passport
ORGANIZE · ASSESS · MATCH
Shared information foundation
Where it goes
Federal · non-dilutive
Private capital · materials only
Evidence returns to the record
Mechanisms we work across
These are the mechanisms we develop applications for. Specific Aims Intelligence is an independent consulting firm and is not affiliated with, endorsed by, or acting on behalf of any federal agency.
The problem
Specific Aims Intelligence creates continuity across the funding lifecycle. We organize what the company knows, identify what is missing, and convert that record into the next appropriate funding or capital product.
The service system
Phase I Build
Prepare a competitive first federal application.
Phase II Autopilot
Build Phase II readiness throughout Phase I.
Federal Extension
Follow-on non-dilutive funding.
Commercial Capital
Investment, licensing, partnership.
Funding Passport
Shared information foundation
Every stage above draws on the same record, so the company does not start from zero at each funding decision.
Funding Passport
It becomes the foundation for funding matching, readiness analysis, proposal development, follow-on funding, and commercial-capital preparation.
The company
The technology
The market
The analysis
Funding Passport is an expert-developed service — not self-service software.
The five services
Create a reusable record of the company's technology, evidence, team, commercialization progress, previous funding, and future capital needs.
Company stage
Any stage — the foundation for everything that follows
Representative outputs
Position the company and prepare a competitive Phase I SBIR or STTR application.
Company stage
Pre-award companies pursuing a first federal application
Representative outputs
What the engagement covers
Help Phase I awardees prepare continuously for Phase II rather than reconstructing progress before the deadline.
Company stage
Active Phase I awardees
Representative outputs
Convert Phase II progress and evidence into appropriate follow-on non-dilutive funding.
Company stage
Companies completing or holding a Phase II award
Representative outputs
Translate verified technical and commercial progress into materials for investment, licensing, and strategic-partnership conversations.
Company stage
Companies with verified technical and commercial progress
Representative outputs
Phase I Build
Outcome
A coherent, submission-ready Phase I application package.Phase II Autopilot
“Autopilot” describes a managed continuity process run by people. It does not autonomously write or submit an application.
Captured continuously through Phase I
After Phase II
We evaluate whether the company’s Phase II results support an appropriate follow-on federal mechanism and convert that progress into the required strategy and application materials.
Possible routes
Not every mechanism is available to every company. Eligibility depends on the agency, the original award, and the evidence.
We help organize technical and commercial progress into materials for investor diligence, licensing conversations, and strategic partnerships.
Materials produced
Specific Aims Intelligence prepares materials and organizes evidence. It is not an investment bank, securities broker, fundraising intermediary, or financial adviser.
How it works
Initial conversation
Company, technology, stage, and funding objective. Enough to tell whether there is anything worth pursuing.
Fit review
Readiness, timing, viable routes, and the constraints that would sink an application before review.
Structured delivery
Scope, responsibilities, and outputs agreed — through your agreement, vendor onboarding, or purchase-order process — then the strategy, development, coordination, and review work itself.
Continuity
What the company learned and produced is preserved and carried into the next funding stage rather than rebuilt.
Who we serve
Specific Aims Intelligence is designed for companies pursuing evidence-driven innovation — not general nonprofit or community grant seeking.
Differentiation
You stop paying — in fees and in your scientists' time — to reassemble the same evidence for every submission. The second application costs a fraction of the first, and the fifth is mostly assembly, because the record already exists.
You find out that a mechanism is wrong before you write to it, not in a summary statement six months later. The most expensive outcome in federal funding is a strong application aimed at the wrong programme, and this is what prevents it.
Every claim in the application can be traced to something that supports it, so reviewers do not find the gap first. The same discipline holds later, when an investor's diligence team reads the identical claims.
A win positions the next stage instead of ending the plan. Phase II preparation is already under way when Phase I closes, and the technical record you built for reviewers is the one investors ask for.
About
Specific Aims Intelligence grew out of a pattern that kept repeating in client conversations. Companies would arrive ready to start writing, and the honest answer was often that they shouldn’t — not yet. The timing was wrong, a piece of evidence was missing, or a factor outside their control made that cycle a poor bet. Some had already paid someone to begin writing before finding this out. Others had the opposite problem: they were underselling what they’d built, positioning for a mechanism well below what their data could support.
Both failures start in the same place. Grant work is usually sold as writing, so it begins at the writing — while the decisions that determine whether an application is competitive happen well before a word is drafted.
This firm was founded by Snider Desir, PhD, whose background spans biomedical research, target validation in pharma, and commercial roles in life-science technology. That combination matters here: evaluating whether a scientific claim is actually supported by its evidence is the same discipline that determines whether a Specific Aims section holds up under review, and the commercialization narrative is an argument about market and adoption, not a section to fill.
FAQ
Consultation
Request a fit review
Or reach us directly — either route gets the same attention.
Prefer to talk
A short conversation about your technology, stage, and funding objective. No preparation required.
Discuss Your Funding StrategyPrefer to write
Send the same details by email and we will reply directly. No call required.
Email Us Directlyspecificaimsintelligence@gmail.comProcurement
Qualified companies may receive a tailored scope of work for internal approval, vendor onboarding, or procurement. A W-9 and vendor information are available on request.
Specific Aims Intelligence LLC · Florida
Next step
Discuss your technology, funding stage, and next objective with Specific Aims Intelligence.